What's behind Medtronic's latest stock surge?

Traders Union
All News
Financial News
Medtronic surges 3.97% today on gains

Highlights

Medtronic acquired SPR Therapeutics for $650 million in cash, adding the SPRINT pain therapy to its portfolio.
The company posted its strongest revenue growth in ten quarters and increased its quarterly dividend to $0.72 per share, yielding 3.6%.
Technical signals show mixed momentum with elevated volatility; price expected to consolidate between $80.81 and $86.53 over the next week.

Revenue growth and dividend hike as SPR acquisition aims for accretion

Medtronic completed a $650 million cash acquisition of SPR Therapeutics, integrating the FDA-cleared SPRINT stimulation system into its portfolio for pain therapy. The company reported its strongest enterprise revenue growth in ten quarters, driven by new product launches and solid uptake in Cardiac Ablation Solutions. Medtronic also increased its quarterly dividend to $0.72 per share, with the move representing an annualized yield of approximately 3.6%. The SPR acquisition is expected to be minimally dilutive to adjusted earnings per share in FY 2027 and neutral to accretive thereafter.

Anton Kharitonov, expert at Traders Union, sees Medtronic’s recent gains as technically vulnerable despite the bullish news headline. He notes that the $650 million SPR Therapeutics deal and dividend increase have provided sentiment lift yet warns that price remains below the 200-day moving average, confirming the longer-term bearish bias. Critical indicators such as the weak ADX and neutral oscillators suggest enthusiasm is unsustainable. Kharitonov believes short- and medium-term demand is likely overextended with downside risk prevailing. "Markets have overreacted to headline growth, while unresolved technical weakness means any further rally may quickly reverse."

Viktoras Karapetjanc, expert at Traders Union, highlights Medtronic’s enhanced fundamentals after the SPR Therapeutics acquisition and sustained revenue growth. He sees the integration of FDA-cleared pain therapies and a raised dividend as clear markers of long-term strategic strength. Karapetjanc believes the market structure remains bullish, especially with strong enterprise growth and new product launches supporting upward momentum. "This setup offers investors robust opportunity, and I expect further growth as management executes on innovation and portfolio expansion."

Jainam Mehta, market strategist, considers Medtronic’s rally technically justified but sees volatility as a tactical signal. He notes that MACD shows strong momentum, yet neutral-to-bearish RSI and positioning below the 200-day moving average hint at possible consolidation or false breakouts. Mehta believes short-term setups favor quick entries on volatility spikes, but warns a drop below $81.81 could trigger sharp reversals. "Current chart dynamics suggest tactical trades only, with a potential breakout above $84.69 offering the next clear inflection point."

Upward momentum limited by long-term resistance and mixed signals

Medtronic is trading above its 20-day and 50-day moving averages at $81.02 and $79.12, while remaining below the 200-day at $90.83. This positioning signals short- and medium-term upward momentum contrasted by lingering long-term bearish alignment, with the Ichimoku Kijun at $81.81 providing near-term support and $84.69 marking immediate resistance. Momentum signals are mixed: Moving Average Convergence Divergence (MACD) gives a strong buy forecast, but the Average Directional Index (ADX) sits at a weak trend level. The Relative Strength Index (RSI) and Stochastic RSI remain neutral to mildly bearish, while Commodity Channel Index (CCI) is also neutral. Bull/Bear Power (BBP) indicates buyers have a slight intraday edge with an oversold context. Medtronic is up $3.20 or 3.97% on the day after opening with an upside gap near 1.57%. The current price is mid-range for the session, and intraday volatility is elevated at 3.70%. Recent price action shows renewed strength, but overall intraday signals are split between buyers and sellers.

Earlier, analysts noted that Medtronic shares were under pronounced bearish pressure as technical resistance weighed on the stock’s momentum. The latest breakout above key short- and medium-term moving averages, bolstered by strong revenue performance and a major acquisition, signals a potential shift in sentiment, making sustained action above $84.69 the pivotal level to confirm a broader recovery.

Source of Data: MDT Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.